结肠癌患者血清中miR-653-5p的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2023.04.003

摘要/Abstract

摘要： 目的：探讨结肠癌患者血清中microRNA miR-653-5p的表达及其临床意义。方法：选取2019年1月—2020年1月在商丘市第一人民医院就诊的76名结肠癌患者作为实验组，以同期76名健康体检者作为对照组。采集研究对象空腹静脉血5 mL，提取血清miRNA，采用实时定量荧光PCR(qPCR)检测血清中miR-653-5p的表达水平。根据miR-653-5p相对表达水平的平均值将实验组结肠癌患者分为高、低表达组，分析miR-653-5p表达与结肠癌临床病理指标之间的相关性；采用受试者工作特征曲线(ROC)分析miR-653-5p的临床诊断价值；采用Kaplan-Meier和多因素COX回归分析结肠癌生存预后的影响因素。结果：对照组人群血清中miR-653-5p的相对表达水平为0.622±1.319，实验组结肠癌患者为0.471±1.076，实验组较对照组明显降低(P<0.01)；结肠癌患者血清中miR-653-5p表达水平与患者临床T分期、远处转移、淋巴结转移、脉管癌栓及肿瘤分化程度相关(均为P<0.01)；miR-653-5p对临床诊断结肠癌的曲线下面积为0.823(P<0.01)，截断值为0.498，敏感性为80.26%，特异性为82.89%；Kaplan-Meier曲线显示miR-653-5p高表达组的结肠癌患者生存率明显高于低表达组(P<0.01)；COX回归分析显示miR-653-5p表达水平、临床T分期、远处转移、淋巴结转移和肿瘤分化程度是影响结肠癌患者预后生存的独立危险因素(均为P<0.01)。结论：结肠癌患者血清中miR-653-5p表达水平明显下调，其可作为结肠癌诊断和预后评估的新型生物标志物。

关键词: 结肠癌, miR-653-5p, 病理指标, 诊断, 预后

Abstract: OBJECTIVE： To investigate expressions of microRNA miR-653-5p in the serum of colon cancer patients and their clinical significance. METHODS： From January 2019 to January 2020，76 colon cancer patients who were treated in the First People’s Hospital of Shangqiu City were selected as the experimental group，and 76 healthy physical examiners in the same period were selected as the observation group. From the collection of 5 mL of fasting venous blood from the subjects，serum miRNA was extracted. Real-time quantitative fluorescence PCR (qPCR) was used to detect expression levels of miR-653-5p，and their differences between the two groups were compared. According to the relative expression level of miR-653-5p，the colon cancer patients in the experimental group were divided into high and low expression groups，and the correlation between miR-653-5p expression and the clinicopathological indicators of colon cancer were analyzed. The clinical diagnostic value of miR-653-5p was analyzed by using the receiver operating characteristic curve (ROC). Kaplan-Meier and multivariate COX regression were used to analyze factors influencing colon cancer survival prognosis. RESULTS： The relative expression level of miR-653-5p in the serum of the control group was 0.622±1.319，and was 0.471±1.076 for the patients，which was significantly lower than that in the control group (P<0.01). There were no significant correlations between the expression levels of miR-653-5p and the sex，age，tumor location and size of colon cancer patients (P>0.05)，but they were related to clinical T stages，distant metastasis，lymph node metastasis，vascular cancer thrombus and tumor differentiation (all P<0.01). The area under the curve of miR-653-5p for clinical diagnosis of colon cancer was 0.823 (P<0.01)，the cut-off value was 0.498，the sensitivity was 80.26%，and the specificity was 82.89%. The Kaplan-Meier curve showed that the survival rate of colon cancer patients in the high-expression group of miR-653-5p was significantly higher than that in the low-expression group (P<0.01). COX regression analysis showed that miR-653-5p expression levels，clinical T stages，distant metastasis，lymph node metastasis，and tumor differentiation were independent risk factors affecting the prognosis and survival of colon cancer patients (all P<0.01). CONCLUSION： The expression levels of miR-653-5p in the serum of colon cancer patients were significantly down-regulated. Our results suggest that miR-653-5p may be a useful and novel biomarker for the diagnosis and prognosis evaluation of colon cancer.

Key words: colorectal cancer, miR-653-5p, pathological indicators, diagnosis, prognosis

中图分类号:

R574

杨程晴, 崔永辉, 郑紫恒. 结肠癌患者血清中miR-653-5p的表达及其临床意义[J]. 癌变·畸变·突变, 2023, 35(4): 261-265.

YANG Chengqing, CUI Yonghui, ZHENG Ziheng. Expression and clinical significance of miR-653-5p in colon cancer patients[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 261-265.

参考文献

[1] CARDOSO R, GUO F, HEISSER T, et al. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study[J]. Lancet Oncol, 2021, 22(7): 1002-1013.
[2] WONG M C S, HUANG J J, LOK V, et al. Differences in incidence and mortality trends of colorectal cancer worldwide based on sex, age, and anatomic location[J]. Clin Gastroenterol Hepatol, 2021, 19(5): 955-966.e61.
[3] CAO W, CHEN H D, YU Y W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J, 2021, 134(7): 783-791.
[4] ALMARIO C V, SHERGILL J, OH J. Measuring and improving quality of colonoscopy for colorectal cancer screening[J]. Tech Innov Gastrointest Endosc, 2022, 24(3): 269-283.
[5] WU Y, JIA H W, ZHOU H Y, et al. Immune and stromal related genes in colon cancer: analysis of tumour microenvironment based on the cancer genome atlas (TCGA) and gene expression omnibus (GEO) databases[J]. Scand J Immunol, 2022, 95(2): e13119.
[6] HILL M, TRAN N. miRNA interplay: mechanisms and consequences in cancer[J]. Dis Model Mech, 2021, 14(4): dmm047662.
[7] MENON A, ABD-AZIZ N, KHALID K, et al. miRNA: a promising therapeutic target in cancer[J]. Int J Mol Sci, 2022, 23(19): 11502.
[8] UZUNER E, ULU G T, GüRLER S B, et al. The role of MiRNA in cancer: pathogenesis, diagnosis, and treatment[J]. Methods Mol Biol, 2022, 2257: 375-422.
[9] WU H S, XU J Y, GONG G L, et al. CircARL8B contributes to the development of breast cancer via regulating miR-653-5p/HMGA2 axis[J]. Biochem Genet, 2021, 59(6): 1648-1665.
[10] OMOROU M, HUANG Y W, LIU N, et al. The emerging role of miR-653 in human cancer[J]. Cancer Epidemiol, 2022, 79: 102208.
[11] 赵黎阳, 崔玲, 张颖, 等. LncRNA PRNCR1靶向miR-653-5p调控鼻咽癌细胞恶性生物学行为[J]. 中国癌症防治杂志, 2021, 13(4): 400-406.
[12] PAN G T, LIU Y H, SHANG L R, et al. EMT-associated microRNAs and their roles in cancer stemness and drug resistance[J]. Cancer Commun, 2021, 41(3): 199-217.
[13] SAYYED A A, GONDALIYA P, BHAT P, et al. Role of miRNAs in cancer diagnostics and therapy: a recent update[J]. Curr Pharm Des, 2022, 28(6): 471-487.
[14] MA J, WANG P L, HUANG L, et al. Bioinformatic analysis reveals an exosomal miRNA-mRNA network in colorectal cancer[J]. BMC Med Genomics, 2021, 14(1): 60.
[15] SU Y J, FENG W L, ZHONG G L, et al. Correction for: ciRs-6 upregulates March1 to suppress bladder cancer growth by sponging miR-653[J]. Aging, 2020, 12(5): 4678-4679.
[16] XING Z S, LI S L, LIU Z X, et al. CircSERPINA3 regulates SERPINA3-mediated apoptosis, autophagy and aerobic glycolysis of prostate cancer cells by competitively binding to miR-653-5p and recruiting BUD13[J]. J Transl Med, 2021, 19(1): 492.
[17] FU L J, HUO J, FITRAT H, et al. CircNRIP1 exerts oncogenic functions in papillary thyroid carcinoma by sponging miR-653-5p and regulating PBX3 expression[J]. J Oncol, 2022, 2022: 2081501.
[18] HAN W, WANG L F, ZHANG L H, et al. Circular RNA circ-RAD23B promotes cell growth and invasion by miR-593-3p/CCND2 and miR-653-5p/TIAM1 pathways in non-small cell lung cancer[J]. Biochem Biophys Res Commun, 2019, 510(3): 462-466.
[19] LI Z L, FAN H, CHEN W W, et al. microRNA-653-5p promotes gastric cancer proliferation and metastasis by targeting the SOCS6-STAT3 pathway[J]. Front Mol Biosci, 2021, 8: 655580.
[20] TOFT J H, -KLAND I, DALEN I. ROC-curves-fundamentals for proper use[J]. Endocrine, 2022, 76(2): 505.
[21] WU Z W, LI Y, ZHANG Y B, et al. Colorectal cancer screening methods and molecular markers for early detection[J]. Technol Cancer Res Treat, 2020, 19: 1533033820980426.
[22] BRETTHAUER M, L-BERG M, WIESZCZY P, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death[J]. N Engl J Med, 2022, 387(17): 1547-1556.
[23] MAHMOUD N N. Colorectal cancer: preoperative evaluation and staging[J]. Surg Oncol Clin N Am, 2022, 31(2): 127-141.